Molecular Partners (MOLN) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Molecular Partners (MOLN) has outperformed Voyager Therapeutics (VYGR) over the past year, gaining 2.7% versus a loss of 47.8%. Over five years, VYGR leads with a -39.8% price change compared with -80.8% for MOLN. Voyager Therapeutics is the larger company by market cap ($152.2 million vs $145.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MOLN | VYGR |
|---|---|---|
| Share price | $3.81 | $2.47 |
| Market cap | $145.94M | $152.20M |
| 1-day change | +0.79% | +0.41% |
| YTD return | -12.59% | -37.15% |
| 1-year return | +2.70% | -47.78% |
| 5-year return | -80.76% | -39.76% |
| EPS (TTM) | $-1.71 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.36 | $5.55 |
| 52-week low | $3.53 | $2.39 |
| Distance from 52-week high | -28.92% | -55.50% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +172.18% | +502.83% |
| Average volume | 1.18K | 566.47K |
| Shares outstanding | 38.31M | 61.62M |
| Employees | 134 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MOLN has outperformed VYGR by 50.5 percentage points over the past year.
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
MOLN vs VYGR FAQ
Which is bigger, Molecular Partners or Voyager Therapeutics?
Voyager Therapeutics (VYGR) is larger, with a market capitalization of $152.20M compared with $145.94M for Molecular Partners (MOLN).
Which stock has performed better over the past year, MOLN or VYGR?
MOLN returned +2.70% over the past 12 months, compared with -47.78% for VYGR (price return, excluding dividends). Past performance does not predict future results.
Are Molecular Partners and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.